Taiwan Seeks Biotech and Pharma Collaborations with India

Taiwan is engaged in an effort to collaborate with India to boost its competitive position in the global life sciences market and counter the dominance of China in pharmaceuticals and biotechnology.

As part of the visit to BioAsia 2025, an important delegation from Taiwan Industrial Biotechnology Association (TIBA) visited Hyderabad to discuss areas for potential investment and collaboration with India's biotech and pharmaceutical companies.

A delegation headed by Mindin Lin, President of Global Bio and Investment, expressed Taiwan's wish to partner India in medical technology, life sciences and pharmaceutical research. The Taiwanese government has been encouraging investment in Taiwan's biotech and pharmaceutical sector through its Biotechnology and Pharmaceutical Industry Promotion Office (BPIPO) to support incoming investors.

The delegation was also taken on a tour of the Genome Valley in Hyderabad, in which they asserted that its research infrastructure was world class. They also visited Bangalore to explore further collaborative opportunities. Shiing-Jer Twu, Chairman, Development Center for Biotechnology (DCB), asserted that Taiwan has notable R&D strength, with over 400 scientists that focus on drug development in the preclinical developmental stage.

Taiwan's expanding had a stretch expansion of the biotechnology landscape and India's emerging pharmaceutical market positions themselves to collaboratively foster innovation and investment, and continue to integrate technology and drive innovation in life sciences and improve healthcare, both countries will be well immersed in a strategic partnership to support future of life sciences and healthcare.

 Dr Gary Gong, Chairman of Innovation to Industry (i2i) said, "While Taiwan has traditionally maintained strong ties with China, geopolitical factors have led us to seek new partnerships. India has emerged as a key ally due to its rapid advancements in pharma, biotech, and healthcare sectors".